Tau imaging: early progress and future directions

@article{Villemagne2015TauIE,
  title={Tau imaging: early progress and future directions},
  author={Victor L. Villemagne and Michelle T. Fodero-Tavoletti and Colin L. Masters and Christopher C. Rowe},
  journal={The Lancet Neurology},
  year={2015},
  volume={14},
  pages={114-124}
}
Use of selective in-vivo tau imaging will enable improved understanding of tau aggregation in the brain, facilitating research into causes, diagnosis, and treatment of major tauopathies such as Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome, chronic traumatic encephalopathy, and some variants of frontotemporal lobar degeneration. Neuropathological studies of Alzheimer's disease show a strong association between tau deposits, decreased cognitive function, and… 
Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions
TLDR
The cross-sectional and longitudinal assessment of the temporal and spatial patterns of tau deposition in the brain will allow a better understanding of the role tau plays in ageing as well as its relationship with cognition, genotype, and neurodegeneration.
Untangling tau imaging
TLDR
The assessment of tau deposition in the brain over time will allow a deeper understanding of the relationship between tau and other variables such as cognition, genotype, and neurodegeneration, as well as assessing the role tau plays in ageing.
Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies
TLDR
The development of tau ligands for imaging studies will be helpful for differential diagnosis and for the development of therapeutic treatments for tauopathies including Alzheimer’s disease.
Tau PET in Neurodegenerative Diseases Manifesting Dementia
TLDR
Recent progress in the development of tau-selective PET tracers and clinical PET studies using these tracers are discussed.
In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings
TLDR
A comprehensive discussion of tau pathophysiology, its quantification with novel PET radiotracers, as well as a systematic review of t Tau PET imaging in normal aging and various dementia conditions, proposing novel directions for future tau research.
In Vivo Tau Imaging for a Diagnostic Platform of Tauopathy Using the rTg4510 Mouse Line
TLDR
The utilities of PET, MRI, and fluorescence imaging for evaluating the disease progression of tauopathy are discussed and in vivo studies on a mouse model of t Tauopathy will provide significant insight into the translational research of neurodegenerative diseases.
Tau PET imaging: present and future directions
TLDR
Recent findings on the most promising tau PET tracers to date are summarized, what has been learnt is discussed, and some suggestions for the next steps that need to be achieved in a near future are offered.
Advances in the development of tau PET radiotracers and their clinical applications
TLDR
In vivo imaging of the tau deposits by positron emission tomography (PET) will facilitate the early and accurate diagnosis of these diseases, tracking of disease progression, assessment of disease severity, and prediction of disease prognosis.
Tau and Ab imaging, CSF measures, and cognition in Alzheimer’s disease
Alzheimer’s disease (AD) is characterized by two molecular pathologies: cerebral b-amyloidosis in the form of b-amyloid (Ab) plaques and tauopathy in the form of neurofibrillary tangles, neuritic
Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
TLDR
How in vivo brain imaging of Aβ pathology has revolutionized the evaluation of patients with clinical AD by providing robust and reproducible statements of global or regional brain Aβ burden and enabling the monitoring of disease progression is described.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 120 REFERENCES
The challenges of tau imaging
TLDR
Development of a tau imaging tracer will enable researchers to noninvasively examine the degree and extent of tau pathology in the brain, quantify changes in tau deposition over time, evaluate its relation to cognition and assess the efficacy of anti-tau therapy.
In vivo tau imaging: Obstacles and progress
TLDR
Progress in the development of selective tau ligands is enabling the noninvasive assessment of the extent of tau pathology in the brain, eventually allowing the quantification of changes in t Tau pathology over time and its relation to cognitive performance, brain volumetrics, and other biomarkers, as well as assessment of efficacy and patient recruitment for antitau therapeutic trials.
The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other Dementias
TLDR
The observations suggest that Aβ deposition is not part of normal ageing, supporting the hypothesis that A β deposition occurs well before the onset of symptoms and is likely to represent preclinical AD.
Neuropathological alterations in Alzheimer disease.
TLDR
Postmortem studies have enabled the staging of the progression of both amyloid and tangle pathologies, and the development of diagnostic criteria that are now used worldwide, and these cross-sectional neuropathological data have been largely validated by longitudinal in vivo studies using modern imaging biomarkers such as amyloids PET and volumetric MRI.
Neurodegenerative tauopathies.
TLDR
Emerging data support the hypothesis that different tau gene mutations are pathogenic because they impair tau functions, promote tau fibrillization, or perturb tAU gene splicing, thereby leading to formation of biochemically and structurally distinct aggregates of tau.
Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies
TLDR
The results of this study suggest that 18F-THK523 selectively binds to paired helical filament tau in AD brains but does not bind to tau lesions in non-AD tauopathies, or to α-synuclein in PD brains.
In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease
TLDR
18F-THK523 does not bind to Aβ in vivo, while following the known distribution of paired helical filaments (PHF)-tau in the brain, and selectively binds to tau in AD patients.
Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls
TLDR
A class of tau ligands, phenyl/pyridinyl-butadienyl-benzothiazoles/benZothiazoliums (PBBs), for visualizing diverse tau inclusions in brains of living patients with AD or non-AD tauopathies and animal models of these disorders are developed.
Transmission and spreading of tauopathy in transgenic mouse brain
TLDR
Transgenic mice expressing mutant (for example, P301S) human tau in nerve cells show the essential features of tauopathies, including neurodegeneration and abundant filaments made of hyperphosphorylated tau protein.
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
TLDR
These projections suggest a prolonged preclinical phase of AD in which Aβ deposition reaches the authors' threshold of positivity at 17·0 (95% CI 14·9-19·9) years, hippocampal atrophy at 4·2 (3·6-5·1] years, and memory impairment at 3·3 (2·5-4·5) years before the onset of dementia (clinical dementia rating score 1).
...
1
2
3
4
5
...